Literature DB >> 25312970

Aberrant miR199a-5p/caveolin1/PPARα axis in hepatic steatosis.

Bo Li1, Zhiguo Zhang1, Huizhi Zhang1, Kai Quan1, Yan Lu1, Dongsheng Cai1, Guang Ning2.   

Abstract

The prevalence of non-alcoholic fatty liver disease (NAFLD), a condition characterized by an excessive accumulation of triglycerides (TGs) in hepatocytes, has dramatically increased globally during recent decades. MicroRNAs (miRs) have been suggested to play crucial roles in many complex diseases and lipid metabolism. Our results indicated that miR199a-5p was remarkably upregulated in free fatty acid (FA)-treated hepatocytes. To investigate the role of miR199a-5p in the pathogenesis of fatty liver and the potential mechanism by which miR199a-5p regulates NAFLD, we first transfected two hepatocyte cell lines, HepG2 and AML12 cells, with agomiR199a-5p or antagomiR199a-5p. Our results indicated that miR199a-5p overexpression exacerbated deposition of FA and inhibited ATP levels and mitochondrial DNA (mtDNA) contents. Consistently, suppression of miR199a-5p partially alleviated deposition of FA and increased ATP levels and mtDNA contents. Moreover, miR199a-5p suppressed the expression of mitochondrial FA β-oxidation-related genes through inhibition of caveolin1 (CAV1) and the related peroxisome proliferator-activated receptor alpha (PPARα) pathway. Furthermore, suppression of CAV1 gene expression by CAV1 siRNA inhibited the PPARα signalling pathway. Finally, we examined the expression of miR199a-5p in liver samples derived from mice fed a high-fat diet, db/db mice, ob/ob mice and NAFLD patients, and found that miR199a-5p was upregulated while CAV1 and PPARA were downregulated in these systems, which was strongly indicative of the essential role of miR199a-5p in NAFLD. In summary, miR199a-5p plays a vital role in lipid metabolism, mitochondrial activity and mitochondrial β-oxidation in liver. Upregulated miR199a-5p in hepatocytes may contribute to impaired FA β-oxidation in mitochondria and aberrant lipid deposits, probably via CAV1 and the PPARα pathway.
© 2014 The authors.

Entities:  

Keywords:  PPARα; caveolin1; fatty acid β-oxidation; miR199a-5p; non-alcoholic fatty liver disease

Mesh:

Substances:

Year:  2014        PMID: 25312970     DOI: 10.1530/JME-14-0127

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  25 in total

Review 1.  Interplay of mitochondrial metabolism and microRNAs.

Authors:  Julian Geiger; Louise T Dalgaard
Journal:  Cell Mol Life Sci       Date:  2016-08-25       Impact factor: 9.261

2.  Systems genetics identifies a co-regulated module of liver microRNAs associated with plasma LDL cholesterol in murine diet-induced dyslipidemia.

Authors:  Alisha R Coffey; Tangi L Smallwood; Jody Albright; Kunjie Hua; Matt Kanke; Daniel Pomp; Brian J Bennett; Praveen Sethupathy
Journal:  Physiol Genomics       Date:  2017-09-15       Impact factor: 3.107

3.  Exosomal miR-199a-5p promotes hepatic lipid accumulation by modulating MST1 expression and fatty acid metabolism.

Authors:  Yuhan Li; Yansong Luan; Jianning Li; Hui Song; Yan Li; Hi Qi; Bo Sun; Peng Zhang; Xianxian Wu; Xing Liu; Yanhui Yang; Wufan Tao; Lei Cai; Zhiwei Yang; Yi Yang
Journal:  Hepatol Int       Date:  2020-10-10       Impact factor: 6.047

Review 4.  Advances of microRNAs in regulating mitochondrial function: new potential application in NAFLD treatment.

Authors:  Chuwei Yu; Jing Chen; Jin Ren
Journal:  Mol Biol Rep       Date:  2022-05-25       Impact factor: 2.742

Review 5.  MicroRNAs and Noncoding RNAs in Hepatic Lipid and Lipoprotein Metabolism: Potential Therapeutic Targets of Metabolic Disorders.

Authors:  Neetu Sud; Jennifer Taher; Qiaozhu Su
Journal:  Drug Dev Res       Date:  2015-08-19       Impact factor: 4.360

Review 6.  MicroRNAs in heart failure: Non-coding regulators of metabolic function.

Authors:  Xiaokan Zhang; P Christian Schulze
Journal:  Biochim Biophys Acta       Date:  2016-08-18

7.  Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway.

Authors:  Alexandra Drakaki; Maria Hatziapostolou; Christos Polytarchou; Christina Vorvis; George A Poultsides; John Souglakos; Vassilis Georgoulias; Dimitrios Iliopoulos
Journal:  BMC Cancer       Date:  2015-07-24       Impact factor: 4.430

Review 8.  MicroRNAs in Nonalcoholic Fatty Liver Disease.

Authors:  György Baffy
Journal:  J Clin Med       Date:  2015-12-04       Impact factor: 4.241

Review 9.  Potential epigenetic mechanism in non-alcoholic Fatty liver disease.

Authors:  Chao Sun; Jian-Gao Fan; Liang Qiao
Journal:  Int J Mol Sci       Date:  2015-03-05       Impact factor: 5.923

10.  Mechanistically linked serum miRNAs distinguish between drug induced and fatty liver disease of different grades.

Authors:  Zhichao Liu; Yuping Wang; Jürgen Borlak; Weida Tong
Journal:  Sci Rep       Date:  2016-04-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.